Naltrexone implant - Shenzhen ScienCare Pharmaceutical
Alternative Names: SK-1801; SK-2007Latest Information Update: 29 Aug 2023
Price :
$50 *
At a glance
- Originator Shenzhen ScienCare Pharmaceutical
- Class Anti-inflammatories; Antineoplastics; Antivirals; Cyclopropanes; Drug withdrawal therapies; Ethers; Eye disorder therapies; Irritable bowel syndrome therapies; Ketones; Morphinans; Non-opioid analgesics; Small molecules
- Mechanism of Action Opioid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Alcoholism
- Phase Unknown Opioid-related disorders
Most Recent Events
- 19 Jul 2023 Investigation in Opioid related disorders in China (SC) (Shenzhen ScienCare Pharmaceutical pipeline, July 2023)
- 16 Jun 2023 Phase-I clinical trials in Alcoholism in China (SC) (NCT05919017)
- 14 Nov 2021 Shenzhen ScienCare Pharmaceutical has patent protection for preparation method of naltrexone implant in USA